Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back.
PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.
Pfizer is now working on a new approach to weight, helping some patients gain weight. Is Pfizer stock a buy or a sell?